Wegovy 7.2mg is available on a prescription-only basis and under medical supervision
Weight loss, however, may be slightly slower compared to non-diabetic populations, likely due to the metabolic resistance created by chronic insulin dysregulation and the weight gain effects of concurrent diabetes medications like sulfonylureas or insulin
Acknowledgements Funding The study and the Rapid Service Fee was supported by funding from Novo Nordisk A/S, which provided consulting fees to Ossian Health Economics and Communications, Basel, Switzerland
Diabetologia 56 (9), 19251933
Exceptions: self-funded employer groups that opted in, Michigan Medicaid (which covers Wegovy as a preferred anti-obesity medication with PA and quantity limits for ages 12 and older), and Medicare (cardiovascular indication only)
Secondary outcomes included individual events, arterial and venous thrombosis, and all-cause mortality